Cerebrospinal fluid exosomal microRNAs as biomarkers for diagnosing or monitoring the progression of non-small cell lung cancer with leptomeningeal metastases
Quick Facts
- Publication title: Cerebrospinal fluid exosomal microRNAs as biomarkers for diagnosing or monitoring the progression of non-small cell lung cancer with leptomeningeal metastases
- Journal: BIOTECHNOL GENET ENG
- Year: 2023
- DOI: 10.1016/j.esmoop.2025.106052
- PMID/PMCID: 41564819; PMC12857322
Research overview
This study assessed the association of corticosteroid dose and second-line immunosuppressants for irAEs with survival outcomes in patients with stage IV NSCLC treated with ICIs. Recent studies have demonstrated that high-dose corticosteroids and second-line immunosuppressants may impair survival of patients with immune-related adverse events (irAEs) upon treatment with immune checkpoint inhibitors (ICIs).
Key findings
1%) received second-line immunosuppressants.
The cumulative corticosteroid dose and use of second-line immunosuppressants were not associated with survival.
Study design
Patients with stage IV NSCLC treated with ICI-based regimens between 2015 and 2022 in the first or second line who received systemic immunosuppressants for irAEs were retrospectively included from 17 hospitals in eight countries worldwide.
Associations of corticosteroid peak and cumulative dose, and use of second-line immunosuppressants with overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) were assessed using Cox proportional hazards regression.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization, miRNA profiling/sequencing and bioinformatic analysis; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Cerebrospinal fluid exosomal microRNAs as biomarkers for diagnosing or monitoring the progression of non-small cell lung cancer with leptomeningeal metastases Biotechnology and Genetic Engineering Reviews. 2023. DOI: 10.1016/j.esmoop.2025.106052. PMID/PMCID: 41564819; PMC12857322.